Cargando…
BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies
In this work, BTEAC (benzyl triethylammonium chloride) was employed as a phase transfer catalyst in an improved synthesis (up to 88% yield) of S-alkylated bromobenzofuran-oxadiazole scaffolds BF1-9. These bromobenzofuran-oxadiazole structural hybrids BF1-9 were evaluated in vitro against anti-hepato...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917671/ https://www.ncbi.nlm.nih.gov/pubmed/36769327 http://dx.doi.org/10.3390/ijms24033008 |
_version_ | 1784886423879417856 |
---|---|
author | Irfan, Ali Zahoor, Ameer Fawad Rasul, Azhar Al-Hussain, Sami A. Faisal, Shah Ahmad, Sajjad Noor, Rida Muhammed, Muhammed Tilahun Zaki, Magdi E. A. |
author_facet | Irfan, Ali Zahoor, Ameer Fawad Rasul, Azhar Al-Hussain, Sami A. Faisal, Shah Ahmad, Sajjad Noor, Rida Muhammed, Muhammed Tilahun Zaki, Magdi E. A. |
author_sort | Irfan, Ali |
collection | PubMed |
description | In this work, BTEAC (benzyl triethylammonium chloride) was employed as a phase transfer catalyst in an improved synthesis (up to 88% yield) of S-alkylated bromobenzofuran-oxadiazole scaffolds BF1-9. These bromobenzofuran-oxadiazole structural hybrids BF1-9 were evaluated in vitro against anti-hepatocellular cancer (HepG2) cell line as well as for their in silico therapeutic potential against six key cancer targets, such as EGFR, PI3K, mTOR, GSK-3β, AKT, and Tubulin polymerization enzymes. Bromobenzofuran structural motifs BF-2, BF-5, and BF-6 displayed the best anti-cancer potential and with the least cell viabilities (12.72 ± 2.23%, 10.41 ± 0.66%, and 13.08 ± 1.08%), respectively, against HepG2 liver cancer cell line, and they also showed excellent molecular docking scores against EGFR, PI3K, mTOR, and Tubulin polymerization enzymes, which are major cancer targets. Bromobenzofuran-oxadiazoles BF-2, BF-5, and BF-6 displayed excellent binding affinities with the active sites of EGFR, PI3K, mTOR, and Tubulin polymerization enzymes in the molecular docking studies as well as in MMGBSA and MM-PBSA studies. The stable bindings of these structural hybrids BF-2, BF-5, and BF-6 with the enzyme targets EGFR and PI3K were further confirmed by molecular dynamic simulations. These investigations revealed that 2,5-dimethoxy-based bromobenzofuran-oxadiazole BF-5 (10.41 ± 0.66% cell viability) exhibited excellent cytotoxic therapeutic efficacy. Moreover, computational studies also suggested that the EGFR, PI3K, mTOR, and Tubulin polymerization enzymes were the probable targets of this BF-5 scaffold. In silico approaches, such as molecular docking, molecular dynamics simulations, and DFT studies, displayed excellent association with the experimental biological data of bromobenzofuran-oxadiazoles BF1-9. Thus, in silico and in vitro results anticipate that the synthesized bromobenzofuran-oxadiazole hybrid BF-5 possesses prominent anti-liver cancer inhibitory effects and can be used as lead for further investigation for anti-HepG2 liver cancer therapy. |
format | Online Article Text |
id | pubmed-9917671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99176712023-02-11 BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies Irfan, Ali Zahoor, Ameer Fawad Rasul, Azhar Al-Hussain, Sami A. Faisal, Shah Ahmad, Sajjad Noor, Rida Muhammed, Muhammed Tilahun Zaki, Magdi E. A. Int J Mol Sci Article In this work, BTEAC (benzyl triethylammonium chloride) was employed as a phase transfer catalyst in an improved synthesis (up to 88% yield) of S-alkylated bromobenzofuran-oxadiazole scaffolds BF1-9. These bromobenzofuran-oxadiazole structural hybrids BF1-9 were evaluated in vitro against anti-hepatocellular cancer (HepG2) cell line as well as for their in silico therapeutic potential against six key cancer targets, such as EGFR, PI3K, mTOR, GSK-3β, AKT, and Tubulin polymerization enzymes. Bromobenzofuran structural motifs BF-2, BF-5, and BF-6 displayed the best anti-cancer potential and with the least cell viabilities (12.72 ± 2.23%, 10.41 ± 0.66%, and 13.08 ± 1.08%), respectively, against HepG2 liver cancer cell line, and they also showed excellent molecular docking scores against EGFR, PI3K, mTOR, and Tubulin polymerization enzymes, which are major cancer targets. Bromobenzofuran-oxadiazoles BF-2, BF-5, and BF-6 displayed excellent binding affinities with the active sites of EGFR, PI3K, mTOR, and Tubulin polymerization enzymes in the molecular docking studies as well as in MMGBSA and MM-PBSA studies. The stable bindings of these structural hybrids BF-2, BF-5, and BF-6 with the enzyme targets EGFR and PI3K were further confirmed by molecular dynamic simulations. These investigations revealed that 2,5-dimethoxy-based bromobenzofuran-oxadiazole BF-5 (10.41 ± 0.66% cell viability) exhibited excellent cytotoxic therapeutic efficacy. Moreover, computational studies also suggested that the EGFR, PI3K, mTOR, and Tubulin polymerization enzymes were the probable targets of this BF-5 scaffold. In silico approaches, such as molecular docking, molecular dynamics simulations, and DFT studies, displayed excellent association with the experimental biological data of bromobenzofuran-oxadiazoles BF1-9. Thus, in silico and in vitro results anticipate that the synthesized bromobenzofuran-oxadiazole hybrid BF-5 possesses prominent anti-liver cancer inhibitory effects and can be used as lead for further investigation for anti-HepG2 liver cancer therapy. MDPI 2023-02-03 /pmc/articles/PMC9917671/ /pubmed/36769327 http://dx.doi.org/10.3390/ijms24033008 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Irfan, Ali Zahoor, Ameer Fawad Rasul, Azhar Al-Hussain, Sami A. Faisal, Shah Ahmad, Sajjad Noor, Rida Muhammed, Muhammed Tilahun Zaki, Magdi E. A. BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies |
title | BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies |
title_full | BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies |
title_fullStr | BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies |
title_full_unstemmed | BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies |
title_short | BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies |
title_sort | bteac catalyzed ultrasonic-assisted synthesis of bromobenzofuran-oxadiazoles: unravelling anti-hepg-2 cancer therapeutic potential through in vitro and in silico studies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917671/ https://www.ncbi.nlm.nih.gov/pubmed/36769327 http://dx.doi.org/10.3390/ijms24033008 |
work_keys_str_mv | AT irfanali bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies AT zahoorameerfawad bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies AT rasulazhar bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies AT alhussainsamia bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies AT faisalshah bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies AT ahmadsajjad bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies AT noorrida bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies AT muhammedmuhammedtilahun bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies AT zakimagdiea bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies |